Publications by authors named "L Fouillet"
Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for real-world data (RWD) evidence in MZL. Real-world data in Lymphoma and survival in Adults (REALYSA) is a prospective multicentric French cohort of newly diagnosed lymphoma patients.
View Article and Find Full Text PDFArticle Synopsis
- Advances in lymphoma treatment have made assessing health-related quality of life (HRQoL) crucial for newly diagnosed patients, yet there's limited information on their HRQoL profiles at diagnosis.
- A study involving 3922 adults with various lymphoma types utilized three validated EORTC questionnaires to evaluate HRQoL at diagnosis, achieving high completion rates between 84% and 88%.
- Findings highlighted significant impairments in global health status across lymphoma subtypes, with factors like gender, performance status, and B symptoms affecting HRQoL, providing valuable insights for future research and clinical practices.
Article Synopsis
- - The phase II trial assessed the effectiveness of the RiBVD treatment (rituximab, bendamustine, velcade, and dexamethasone) in patients over 65 with mantle cell lymphoma (MCL), which resulted in a median progression-free survival of 79 months and overall survival of 111 months.
- - TP53 mutation status and albumin levels were identified as significant prognostic factors, with TP53 mutations linked to a higher risk of shorter progression-free survival and overall survival in the analyzed patient population.
- - A scoring system combining TP53 mutation status and albumin levels allowed differentiation of patient outcomes, indicating varying survival rates based on the presence of these factors, thus enhancing prognostic assessments
Article Synopsis
- Real-world data (RWD) are crucial for enhancing clinical trial (CT) findings, but challenges like data quality persist; the REALYSA study, launched in 2018, focuses on newly diagnosed lymphoma patients in France.
- A proof-of-concept analysis of 645 patients with diffuse large B-cell lymphoma (DLBCL) found high data completeness (<4% missing) and revealed good survival rates, with a median follow-up of 9.9 months showing 1-year event-free survival of 77.9% and overall survival of 90.0%.
- The study also assessed how well REALYSA's patient outcomes matched those from recent phase 3 trials (POLARIX and SENIOR), demonstrating